A Systematic Patent Review (2008-2023) for Treatment in Pregnancy

Kélle   Velasques   Pereira; Camila   Oliveira   Pacheco; Izabel   Almeida   Alves; Sandra   Elisa   Haas
Abstract

Introduction: During pregnancy, the woman’s body undergoes anatomical and physiological changes, making this period susceptible to maternal-fetal diseases and complications. The consequences of not treating pregnant women include premature birth, low birth weight fetuses, and postnatal behavior disorders. Developing new therapies can accelerate the discovery of safe and effective drugs, contributing to designing novel natural and synthetic products to treat complications the pregnancy.
Objective: This study aimed to carry out a patent review to identify and explore trends in innovation and therapeutic strategies for treating pregnant women.
Methods: The Espacenet and WIPO databases were used, with the inclusion criteria being the keywords “pregnancy and drug” and code A61k, from 2008 to 2023, and as exclusion were the access to the patent and focus on human pregnant women.
Results: After the final screening, 32 patents were selected, with strategies for the treatment of diseases in pregnant women. Of these, 20 patents are on preclinical studies on animals and 12 on pregnant women. It was observed that universities lead the ranking of applications (17/32), and China has the highest number of patents (18/32). Most findings contain herbal medicines and/or the association of natural extracts with synthetic drugs.
Conclusion: From this perspective, new drug administration systems were also developed, which can be a promising source for obtaining new medicines for the treatment of pregnant women; however, research is still limited and shows a gap in stimulating the rapid development of safe drugs that improve the health of pregnant women.
Keywords: Pregnancy, drug, diseases, natural products, medicinal, innovation.
[1]
Kazma, J.M.; van den Anker, J.; Allegaert, K.; Dallmann, A.; Ahmadzia, H.K. Anatomical and physiological alterations of pregnancy. J. Pharmacokinet. Pharmacodyn.,  2020, 47(4), 271-285.
 [http://dx.doi.org/10.1007/s10928-020-09677-1] [PMID: 32026239]

[2]
Cabrera, R.M.; Linda Lin, Y.; Law, E.; Kim, J.; Wlodarczyk, B.J. The teratogenic effects of sertraline in mice. Birth Defects Res.,  2020, 112(13), 1014-1024.
 [http://dx.doi.org/10.1002/bdr2.1660] [PMID: 32077266]

[3]
Dabb, C.; Dryer, R.; Brunton, R.J.; Yap, K.; Roach, V.J. Paternal pregnancy-related anxiety: Systematic review of men’s concerns and experiences during their partners’ pregnancies. J. Affect. Disord.,  2023, 323, 640-658.
 [http://dx.doi.org/10.1016/j.jad.2022.11.092] [PMID: 36481231]

[4]
Racicot, K.; Kwon, J.Y.; Aldo, P.; Silasi, M.; Mor, G. Understanding the complexity of the immune system during pregnancy. Am. J. Reprod. Immunol.,  2014, 72(2), 107-116.
 [http://dx.doi.org/10.1111/aji.12289] [PMID: 24995526]

[5]
Shook, L.L.; Kislal, S.; Edlow, A.G. Fetal brain and placental programming in maternal obesity: A review of human and animal model studies. Prenat. Diagn.,  2020, 40(9), 1126-1137.
 [http://dx.doi.org/10.1002/pd.5724] [PMID: 32362000]

[6]
Alegre-Del Rey, E.J.; Fénix-Caballero, S.; Díaz-Navarro, J. Risk of medications in pregnancy: A problem of knowledge transfer with ethical repercussions. Cuad. Bioet.,  2019, 30(99), 199-207.
 [PMID: 31206299]

[7]
Sun, C.; Groom, K.M.; Oyston, C.; Chamley, L.W.; Clark, A.R.; James, J.L. The placenta in fetal growth restriction: What is going wrong? Placenta,  2020, 96, 10-18.
 [http://dx.doi.org/10.1016/j.placenta.2020.05.003] [PMID: 32421528]

[8]
Marx, U.; Akabane, T.; Andersson, T.B.; Baker, E.; Beilmann, M.; Beken, S.; Brendler-Schwaab, S.; Cirit, M.; David, R.; Dehne, E.M.; Durieux, I.; Ewart, L.; Fitzpatrick, S.C.; Frey, O.; Fuchs, F.; Griffith, L.G.; Hamilton, G.A.; Hartung, T.; Hoeng, J.; Hogberg, H.; Hughes, D.J.; Ingber, D.E.; Iskandar, A.; Kanamori, T.; Kojima, H.; Kuehnl, J.; Leist, M.; Li, B.; Loskill, P.; Mendrick, D.L.; Neumann, T.; Pallocca, G.; Rusyn, I.; Smirnova, L.; Steger-Hartmann, T.; Tagle, D.A.; Tonevitsky, A.; Tsyb, S.; Trapecar, M.; Van de Water, B.; Van den Eijnden-van Raaij, J.; Vulto, P.; Watanabe, K.; Wolf, A.; Zhou, X.; Roth, A. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. Altern. Anim. Exp.,  2020, 37(3), 365-394.
 [PMID: 32113184]

[9]
Mitchell, A.A. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol,  2011, 51.

[10]
David, A.L.; Ahmadzia, H.; Ashcroft, R.; Bucci-Rechtweg, C.; Spencer, R.N.; Thornton, S. Improving development of drug treatments for pregnant women and the fetus. Ther. Innov. Regul. Sci.,  2022, 56(6), 976-990.
 [http://dx.doi.org/10.1007/s43441-022-00433-w] [PMID: 35881237]

[11]
Waggoner, M.R.; Lyerly, A.D. Clinical trials in pregnancy and the “shadows of thalidomide”: Revisiting the legacy of Frances Kelsey. Contemp. Clin. Trials,  2022, 119, 106806.
 [http://dx.doi.org/10.1016/j.cct.2022.106806] [PMID: 35654303]

[12]
Figueroa-Espada, C.G.; Hofbauer, S.; Mitchell, M.J.; Riley, R.S. Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy. Adv. Drug Deliv. Rev.,  2020, 160, 244-261.
 [http://dx.doi.org/10.1016/j.addr.2020.09.006] [PMID: 32956719]

[13]
Giacomeli, R.; Guerra Teixeira, F.E.; Carvalho, F.B.; Pacheco, C.O.; Martins Parisotto, A.J.; Funguetto Ribeiro, A.C.; Gomes de Gomes, M.; Haas, S.E. Curcumin-loaded poly(ϵ-caprolactone) lipid-core nanocapsules: Evaluation of fetal and maternal toxicity. Food Chem. Toxicol.,  2020, 144, 111625.
 [http://dx.doi.org/10.1016/j.fct.2020.111625] [PMID: 32738367]

[14]
Sueth-Santiago, V. Curcumin, the golden powder of turmeric: insights into chemistry and biological activities. Quim. Nova,  2015, 38, 538-552.

[15]
Mendes, M.L.S.; Melo, D.R.A. Technology assessment: A methodological proposal. Contemp. Adm. Mag.,  2017, 21(4), 569-584.
 [http://dx.doi.org/10.1590/1982-7849rac2017170047]

[16]
Ponta, L.; Puliga, G.; Manzini, R. A measure of innovation performance: The Innovation Patent Index. Manage. Decis.,  2021, 59(13), 73-98.
 [http://dx.doi.org/10.1108/MD-05-2020-0545]

[17]
Ribeiro, B.; Shapira, P. Private and public values of innovation: A patent analysis of synthetic biology. Res. Policy,  2020, 49(1), 103875.
 [http://dx.doi.org/10.1016/j.respol.2019.103875] [PMID: 32015589]

[18]
Han, Y.J. Measuring industrial knowledge stocks with patents and papers. J. Informetrics,  2007, 1(4), 269-276.
 [http://dx.doi.org/10.1016/j.joi.2007.06.001]

[19]
Cockburn, I.; Long, G. The importance of patents to innovation: Updated cross-industry comparisons with biopharmaceuticals. Expert Opin. Ther. Pat.,  2015, 25(7), 739-742.
 [http://dx.doi.org/10.1517/13543776.2015.1040762] [PMID: 25927945]

[20]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ,  2021, 372, n71.
 [http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]

[21]
Geum, Y.; Kim, M. How to identify promising chances for technological innovation: Keygraph-based patent analysis. Adv. Eng. Inform.,  2020, 46, 101155.
 [http://dx.doi.org/10.1016/j.aei.2020.101155]

[22]
Dantas, S.L.C.; Oliveira, G.Y.M.; Costa, K.F.L.; Barros, A.A.; Chaves, E.M.C.; Carvalho, R.E.F.L. Experimental studies in the gestational period: overview of scientific production. Rev. Esc. Enferm. USP,  2018, 52(0), 52.
 [http://dx.doi.org/10.1590/s1980-220x2017024403325]

[23]
Bannerman, S. The world intellectual property organization and the sustainable development agenda. Futures,  2020, 122, 102586.
 [http://dx.doi.org/10.1016/j.futures.2020.102586]

[24]
Palazzani, L. Clinical trials in the time of a pandemic: Implications for informed consent. BioLaw J.,  2021, (2S), 35-50.

[25]
Joshi, M.D. Drug delivery during pregnancy: How can nanomedicine be used?; Future Science, 2017. 

[26]
Ambros-Rudolph, C.M. Disorders of pregnancy. In: Braun-Falco´s Dermatology; Springer, 2022; pp. 1501-1512.
 [http://dx.doi.org/10.1007/978-3-662-63709-8_81]

[27]
Cairns, A.E.; Tucker, K.L.; Leeson, P.; Mackillop, L.; McManus, R.J. Survey of healthcare professionals regarding adjustment of antihypertensive medication(s) in the postnatal period in women with hypertensive disorders of pregnancy. Pregnancy Hypertens.,  2016, 6(4), 256-258.
 [http://dx.doi.org/10.1016/j.preghy.2016.08.240] [PMID: 27939462]

[28]
Malha, L.; Podymow, T.; August, P. Hypertension in pregnancy. In: Hypertension; Elsevier, 2024; pp. 501-517.
 [http://dx.doi.org/10.1016/B978-0-323-88369-6.00044-X]

[29]
Zhang, B.; Liang, R.; Zheng, M.; Cai, L.; Fan, X. Surface- functionalized nanoparticles as efficient tools in targeted therapy of pregnancy complications. Int. J. Mol. Sci.,  2019, 20(15), 3642.
 [http://dx.doi.org/10.3390/ijms20153642] [PMID: 31349643]

[30]
Kamilevna, P.M.M. Method for preeclampsia prevention; World Intellectual Property Organization.: Russian, 2019. 

[31]
Kuciene, R.; Dulskiene, V. Associations of maternal gestational hypertension with high blood pressure and overweight/obesity in their adolescent offspring: A retrospective cohort study. Sci. Rep.,  2022, 12(1), 3800.
 [http://dx.doi.org/10.1038/s41598-022-07903-z] [PMID: 35260718]

[32]
Phipps, E.A.; Thadhani, R.; Benzing, T.; Karumanchi, S.A. Pre-eclampsia: Pathogenesis, novel diagnostics and therapies. Nat. Rev. Nephrol.,  2019, 15(5), 275-289.
 [http://dx.doi.org/10.1038/s41581-019-0119-6] [PMID: 30792480]

[33]
Yanjuan, B.I. Obstetrical and gynecological drug for treating complications of pregnancy and preparation method thereof. In: Espacenet; Ltd, B.Y.T.C., Ed.; China, 2018. 

[34]
Zhou, L. Astragalus membranaceus and Salvia miltiorrhiza ameliorate hypertensive renal damage through lncRNA-mRNA coexpression network. BioMed Res Int,  2022, 2022, 3002353.
 [http://dx.doi.org/10.1155/2022/3002353]

[35]
Fangjun, X.I.A. Drug for department of obstetrics and gynecology for treating pregnancy complication and manufacturing method thereof. C.N. Patent 104258292A, 2015.

[36]
Du, T.T.H.U.T.D.U.X. Use of zanamivir in preparation of drug for treating or preventing preeclampsia. W.O. Patent 2022111543, 2022.

[37]
Lu, Y.; Chen, R.; Cai, J.; Huang, Z.; Yuan, H. The management of hypertension in women planning for pregnancy. Br. Med. Bull.,  2018, 128(1), 75-84.
 [http://dx.doi.org/10.1093/bmb/ldy035] [PMID: 30371746]

[38]
Honigberg, M.C.; Zekavat, S.M.; Aragam, K.; Klarin, D.; Bhatt, D.L.; Scott, N.S.; Peloso, G.M.; Natarajan, P. Long-term cardiovascular risk in women with hypertension during pregnancy. J. Am. Coll. Cardiol.,  2019, 74(22), 2743-2754.
 [http://dx.doi.org/10.1016/j.jacc.2019.09.052] [PMID: 31727424]

[39]
Hyo-eun, B.Y. Composition comprising htr3a agonist for preventing arrhythmia or cardiac death. K.R. Patent 101694780, 2017.

[40]
Li, C.; Jia, W.; Yang, J.; Cheng, C.; Olaleye, O.E. Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines. Acta Pharmacol. Sin.,  2022, 43(12), 3080-3095.
 [http://dx.doi.org/10.1038/s41401-022-00983-7] [PMID: 36114271]

[41]
Xiaoyun, J. CN106668023 Drug composition for treating pregnancy-induced hypertension. C.N. Patent 106668023, 2017.

[42]
Lind, J.M.; Hennessy, A.; Chiu, C.L. Association between a woman’s age at first birth and high blood pressure. Medicine,  2015, 94(16), e697.
 [http://dx.doi.org/10.1097/MD.0000000000000697] [PMID: 25906097]

[43]
Xiaowei, H.Y.; Guo, C.N. Obstetrics and gynecology drug for treating complication of pregnancy and preparation method thereof. C.N. Patent 109893586 , 2017.

[44]
Wang, H.; Rolls, E.T.; Du, X.; Du, J.; Yang, D.; Li, J.; Li, F.; Cheng, W.; Feng, J. Severe nausea and vomiting in pregnancy: psychiatric and cognitive problems and brain structure in children. BMC Med.,  2020, 18(1), 228.
 [http://dx.doi.org/10.1186/s12916-020-01701-y] [PMID: 32867775]

[45]
Bustos, M.; Venkataramanan, R.; Caritis, S. Nausea and vomiting of pregnancy - What’s new? Auton. Neurosci.,  2017, 202, 62-72.
 [http://dx.doi.org/10.1016/j.autneu.2016.05.002] [PMID: 27209471]

[46]
Res, F.B.S. Drug composition for treating vomiting during pregnancy. C.N. Patent 103432126A, 2013.

[47]
Abramowitz, A.; Miller, E.S.; Wisner, K.L. Treatment options for hyperemesis gravidarum. Arch. Women Ment. Health,  2017, 20(3), 363-372.
 [http://dx.doi.org/10.1007/s00737-016-0707-4] [PMID: 28070660]

[48]
Mandaogade, P.M.; Ma, D.; Talwar, N. Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing. C.N. Patent 2858478A1, 2014.

[49]
Zhenhua, H. Pharmaceutical composition for gestation reaction and method of preparing the same. C.N. Patent 101138621, 2008.

[50]
Allais, G.; Chiarle, G.; Sinigaglia, S.; Mana, O.; Benedetto, C. Migraine during pregnancy and in the puerperium. Neurol. Sci.,  2019, 40(S1)(Suppl. 1), 81-91.
 [http://dx.doi.org/10.1007/s10072-019-03792-9] [PMID: 30880362]

[51]
Burch, R.C.; Buse, D.C.; Lipton, R.B. Migraine. Neurol. Clin.,  2019, 37(4), 631-649.
 [http://dx.doi.org/10.1016/j.ncl.2019.06.001] [PMID: 31563224]

[52]
Jin Gp, J.X.Z.H.Z.E.H. Medicine for treating migraine during pregnancy. C.N. Patent 111481625, 2020.

[53]
Islam, A.; Fawad, A.; Shah, A.A.; Jadoon, H.; Sarwar, I.; Abbasi, A.U. Analysis of two years cases of ectopic pregnancy. J. Ayub Med. Coll. Abbottabad,  2017, 29(1), 65-67.
 [PMID: 28712177]

[54]
Xinglan, L. Medicine taken orally for the treatment of old ectopic pregnancy and method of preparation thereof. C.N. Patent 104800434, 2015.

[55]
Vladimirovich, Z.R.S. Method for preventing chronic hypoxia and foetal development retardation. R.U. Patent 0002699559, 2019.

[56]
Zavadenko, N.N.; Suvorinova, N.Iu.; Rumiantseva, M.V.; Ovchinnikova, A.A. The use of instenon in children with minimal brain dysfunction. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova,  2002, 102(5), 29-35.
 [PMID: 12087730]

[57]
Sorouri, K.; Loren, A.W.; Amant, F.; Partridge, A.H. Patient-centered care in the management of cancer during pregnancy. Am. Soc. Clin. Oncol. Educ. Book,  2023, 43(43), e100037.
 [http://dx.doi.org/10.1200/EDBK_100037] [PMID: 37220323]

[58]
Piccinni, G.; Clark, C.; Cagnazzo, E. Acute abdomen of non-obstetric origin in pregnancy.  In: Practical Guide to Simulation in Delivery Room Emergencies; Springer, 2023; pp. 97-112.
 [http://dx.doi.org/10.1007/978-3-031-10067-3_5]

[59]
Zachariah, S.K.; Fenn, M.; Jacob, K.; Arthungal, S.A.; Zachariah, S.A. Management of acute abdomen in pregnancy: Current perspectives. Int. J. Womens Health,  2019, 11, 119-134.
 [http://dx.doi.org/10.2147/IJWH.S151501] [PMID: 30804686]

[60]
Lei, S.D. Drug for treating abdominal pain during pregnancy. C.N. Patent 103386001, 2013.

[61]
Hualun, D. Chinese herbal medicine for curing hypogastric pain in pregnancy for women. C.N. Patent 101904965, 2010.

[62]
Barbitoff, Y.A.; Tsarev, A.A.; Vashukova, E.S.; Maksiutenko, E.M.; Kovalenko, L.V.; Belotserkovtseva, L.D.; Glotov, A.S. A data-driven review of the genetic factors of pregnancy complications. Int. J. Mol. Sci.,  2020, 21(9), 3384.
 [http://dx.doi.org/10.3390/ijms21093384] [PMID: 32403311]

[63]
Zhibin, L.H. Novel application of Chinese herbal compound pharmaceutical composition. C.N. Patent 104352711, 2015.

[64]
Hao, C. Nutrient preparation for promoting pregnancy and preventing miscarriage. C.N. Patent 109288067, 2019.

[65]
Sharifi-Rad, M.; Anil Kumar, N.V.; Zucca, P.; Varoni, E.M.; Dini, L.; Panzarini, E.; Rajkovic, J.; Tsouh Fokou, P.V.; Azzini, E.; Peluso, I.; Prakash Mishra, A.; Nigam, M.; El Rayess, Y.; Beyrouthy, M.E.; Polito, L.; Iriti, M.; Martins, N.; Martorell, M.; Docea, A.O.; Setzer, W.N.; Calina, D.; Cho, W.C.; Sharifi-Rad, J. Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. Front. Physiol.,  2020, 11, 694.
 [http://dx.doi.org/10.3389/fphys.2020.00694] [PMID: 32714204]

[66]
Kamilevna, P.M.M.; Olina Anna, A.; Sadykova, G. Method of treatment of threatened preterm labor. World Intellectual Property Organization. R.U. Patent 0002578476, 2016.

[67]
Chechko, N.; Losse, E.; Nehls, S. Pregnancy denial: Toward a new understanding of the underlying mechanisms. Curr. Psychiatry Rep.,  2023, 25(10), 493-500.
 [http://dx.doi.org/10.1007/s11920-023-01448-2] [PMID: 37597131]

[68]
Wicklow, B.; Retnakaran, R. Gestational diabetes mellitus and its implications across the life span. Diabetes Metab. J.,  2023, 47(3), 333-344.
 [http://dx.doi.org/10.4093/dmj.2022.0348] [PMID: 36750271]

[69]
Choudhury, A.A.; Devi Rajeswari, V. Gestational diabetes mellitus - A metabolic and reproductive disorder. Biomed. Pharmacother.,  2021, 143, 112183.
 [http://dx.doi.org/10.1016/j.biopha.2021.112183] [PMID: 34560536]

[70]
Kim, S.Y.; England, L.; Wilson, H.G.; Bish, C.; Satten, G.A.; Dietz, P. Percentage of gestational diabetes mellitus attributable to overweight and obesity. Am. J. Public Health,  2010, 100(6), 1047-1052.
 [http://dx.doi.org/10.2105/AJPH.2009.172890] [PMID: 20395581]

[71]
Wikens, C.L.W.K.L. Use of lactic acid bacteria for treating or preventing gestational diabetes mellitus. R.U. Patent 0002769312, 2022.

[72]
Mhata, N.T.; Ntlantsana, V.; Tomita, A.M.; Mwambene, K.; Saloojee, S. Prevalence of depression, anxiety and burnout in medical students at the University of Namibia. S. Afr. J. Psychiatry,  2023, 29(1), 2044.
 [http://dx.doi.org/10.4102/sajpsychiatry.v29i0.2044] [PMID: 37292521]

[73]
Yuan, L.; Li, Y.; Yan, H.; Xiao, C.; Liu, D.; Liu, X.; Guan, Y.; Yu, B. Effects of work-family conflict and anxiety in the relationship between work-related stress and job burnout in Chinese female nurses: A chained mediation modeling analysis. J. Affect. Disord.,  2023, 324, 309-316.
 [http://dx.doi.org/10.1016/j.jad.2022.12.112] [PMID: 36586602]

[74]
Keshavarz, M.; Amzajerdi, A.; Montazeri, A.; Bekhradi, R. Effect of mint aroma on nausea, vomiting and anxiety in pregnant women. J. Family Med. Prim. Care,  2019, 8(8), 2597-2601.
 [http://dx.doi.org/10.4103/jfmpc.jfmpc_480_19] [PMID: 31548939]

[75]
Fang, W. Medicinal vinegar preventing and treating anxiety in pregnancy caused by yin deficiency; WIPO: China, 2018. 

[76]
Siddiqui, S.A.; Ali Redha, A.; Snoeck, E.R.; Singh, S.; Simal-Gandara, J.; Ibrahim, S.A.; Jafari, S.M. Anti-depressant properties of crocin molecules in saffron. Molecules,  2022, 27(7), 2076.
 [http://dx.doi.org/10.3390/molecules27072076] [PMID: 35408474]

[77]
Bianzhu, C. Vinegar preparation preventing and treating dizziness in pregnancy caused by qi and blood deficiency. C.N. Patent 108635462, 2018.

[78]
Wang, XiaoMeng Impact of Qi-invigorating traditional Chinese medicines on intestinal flora: A basis for rational choice of prebiotics. Chin J Nat Med.,  2017, 15(4), 241-254.

[79]
Bravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, J.F. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA,  2011, 108(38), 16050-16055.
 [http://dx.doi.org/10.1073/pnas.1102999108] [PMID: 21876150]

[80]
Slickerman, R. Use of lactic acid bacteria for treatment or prevention of at least one condition of postnatal depression and postnatal anxiety R.U. Patent 0002763172, 2021.

[81]
Liang, H.; Yan, J. Infection and Sepsis, in Explosive Blast Injuries: Principles and Practices; Springer, 2023, pp. 227-252.
 [http://dx.doi.org/10.1007/978-981-19-2856-7_15]

[82]
Anatol’evich, M.V.I. Drug preparation for toxicosis relief in early pregnancy exhibiting immune corrective, diuretic action. R.U. Patent 02381032, 2010.

[83]
FÁTima, De. Molecules that stimulate the immune system for treatment of drug addiction, methods of synthesis, antidrug vaccine and uses. W.O. Patent 2019021140, 2019.

[84]
Dahan, O. Birthing as an experience of awe: Birthing consciousness and its long-term positive effects. J. Theor. Philos. Psychol.,  2023, 43(1), 16-30.
 [http://dx.doi.org/10.1037/teo0000214]

[85]
Gau, M.L.; Chang, C.Y.; Tian, S.H.; Lin, K.C. Effects of birth ball exercise on pain and self-efficacy during childbirth: A randomised controlled trial in Taiwan. Midwifery,  2011, 27(6), e293-e300.
 [http://dx.doi.org/10.1016/j.midw.2011.02.004] [PMID: 21459499]

[86]
Haipeng, S.J.; Zhang, J.; Guo, C.N. Traditional chinese medicine composition for promoting head delivery of mares at late pregnancy. C.N. Patent 103800594, 2014.

[87]
Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod.,  2016, 79(3), 629-661.
 [http://dx.doi.org/10.1021/acs.jnatprod.5b01055] [PMID: 26852623]

[88]
Xu, Y.X.Z.; Xi, S.; Qian, X. Evaluating traditional chinese medicine and herbal products for the treatment of gestational diabetes mellitus. J. Diabetes Res., 2019.
 [http://dx.doi.org/10.1155/2019/9182595]

[89]
Illamola, S.M.; Amaeze, O.U.; Krepkova, L.V.; Birnbaum, A.K.; Karanam, A.; Job, K.M.; Bortnikova, V.V.; Sherwin, C.M.T.; Enioutina, E.Y. Use of herbal medicine by pregnant women: What physicians need to know. Front. Pharmacol.,  2020, 10, 1483.
 [http://dx.doi.org/10.3389/fphar.2019.01483] [PMID: 31998122]

[90]
Brown, B.; Wright, C. Safety and efficacy of supplements in pregnancy. Nutr. Rev.,  2020, 78(10), 813-826.
 [http://dx.doi.org/10.1093/nutrit/nuz101] [PMID: 31925443]

[91]
Shand, A.W.; Walls, M.; Chatterjee, R.; Nassar, N.; Khambalia, A.Z. Dietary vitamin, mineral and herbal supplement use: A cross-sectional survey of before and during pregnancy use in Sydney, Australia. Aust. N. Z. J. Obstet. Gynaecol.,  2016, 56(2), 154-161.
 [http://dx.doi.org/10.1111/ajo.12414] [PMID: 26490392]

[92]
Zhao, X.; Jiang, Y.; Zhao, Y.; Xi, H.; Liu, C.; Qu, F.; Feng, X. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur. J. Clin. Microbiol. Infect. Dis.,  2020, 39(7), 1209-1220.
 [http://dx.doi.org/10.1007/s10096-020-03897-6] [PMID: 32328850]

[93]
de Araújo, T.E.; Milián, I.C.B.; de Souza, G.; da Silva, R.J.; Rosini, A.M.; Guirelli, P.M.; Franco, P.S.; Barbosa, B.F.; Ferro, E.A.V.; da Costa, I.N. Experimental models of maternal–fetal interface and their potential use for nanotechnology applications. Cell Biol. Int.,  2020, 44(1), 36-50.
 [http://dx.doi.org/10.1002/cbin.11222] [PMID: 31469205]

[94]
Joshi, G.; Patel, M.; Chaudhary, D.; Sawant, K. Preparation and surface modification of polymeric nanoparticles for drug delivery: State of the art. Recent Pat. Drug Deliv. Formul.,  2021, 14(3), 201-213.
 [http://dx.doi.org/10.2174/1872211314666200904105036] [PMID: 32885767]

[95]
Jian, F.X. Placenta targeted delivery system and preparation method and application thereof. C.N. Patent 109568268, 2019.

[96]
Xietong, J.Y. Preparation of placenta targeted nano-drug and application of placenta targeted nano-drug in treatment of pregnancy combined with autoimmune diseases. C.N. Patent 115054587, 2022.

[97]
Cabral, H. Pharmaceutical composition for administration to pregnant women or women who may be pregnant. W.O. Patent 2020209379, 2020.

[98]
Masafumi, M.E.; Tsujimoto, J.P. Drug for controlling labor pain and treating premature birth. J.P. Patent 2009269823, 2009.

[99]
John, M.S. Medical drug delivery systems. U.S. Patent 20200222628, 2020.

[100]
Peng, J. Device for applying medicine to vagina during pregnancy. C.N. Patent 215309581, 2021.

[101]
Yu, W.H.; Wang, Q.; Kong, C.N. Gelatin sponge drug-loaded particle and preparation method thereof. C.N. Patent 110638762, 2020.
Cite As
Current Medicinal Chemistry

A Systematic Patent Review (2008-2023) for Treatment in Pregnancy

Abstract
